Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AWT 020

Next Previous
Drug Profile

AWT 020

Alternative Names: AWT-020

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anwita Biosciences
  • Developer Anwita Biosciences; Shanghai Junshi Biosciences
  • Class Antineoplastics; Drug conjugates; Immunotherapies; Interleukins; Recombinant fusion proteins; Single-domain antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 2 receptor agonists; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 21 Feb 2025 Phase-I clinical trials in Cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Combination therapy) in China (IV) (NCT06839105)
  • 21 Feb 2025 Phase-I clinical trials in Cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Monotherapy) in China (IV) (NCT06839105)
  • 14 Feb 2025 Shanghai Junshi Bioscience plans a phase I trial for Solid tumors (Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater, Unresectable/Inoperable, Metastatic disease) in China in February 2025 (IV) (NCT06839105)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top